At-Home Sublingual Ketamine Telehealth: Expanding Access to Effective Mental Health Treatment

Introduction: At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression

As mental health concerns continue to rise globally, the need for accessible and effective treatment options becomes more urgent. Traditional antidepressants, while beneficial for some, often come with long delays before relief is felt and may not be effective for everyone. In this context, a novel 2022 study by Hull et al., published in the Journal of Affective Disorders, offers a promising new model of care: “At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial.“

This landmark trial evaluated the real-world impact of delivering ketamine-assisted therapy (KAT) via sublingual tablets to patients in their homes through a telehealth platform. With over 1,200 participants, this study represents one of the largest ketamine effectiveness trials to date.

Understanding the Challenge: Barriers in Mental Health Treatment

Millions of individuals worldwide face major depressive disorder (MDD) and generalized anxiety disorder (GAD), often with significant impacts on daily functioning and quality of life. Despite increased awareness, many face substantial barriers to accessing timely and effective care—including geographic limitations, stigma, and cost.

Ketamine, originally used as an anesthetic, has emerged in recent years as a fast-acting agent capable of rapidly alleviating symptoms of depression and anxiety. Most studies until now have focused on intravenous or intranasal administration under clinical supervision. However, at-home, sublingual administration opens new avenues for expanding access—especially when coupled with robust telehealth monitoring.

Study Design: A Large-Scale, Real-World Trial

Hull et al. conducted a prospective, open-label effectiveness trial involving 1,247 patients diagnosed with moderate to severe depression or anxiety. Participants received sublingual ketamine lozenges and participated in telehealth-based care.

Key features of the study included:

• Use of validated self-report outcome measures (PHQ-9 for depression and GAD-7 for anxiety)
• Remote patient screening and follow-up
• Tracking of side effects, dissociative responses, and clinical outcomes

The study also used unsupervised machine learning to analyze patient response patterns, providing novel insights into differential treatment effects across subpopulations.

Results: Strong Outcomes for Depression and Anxiety

The findings were both robust and encouraging:

• 62.8% of participants reported a 50% or greater reduction in PHQ-9 scores, with an effect size of d = 1.61.
• 62.9% saw similar improvement on the GAD-7 scale, with d = 1.56.
• Remission rates were 32.6% for depression and 31.3% for anxiety.
• Only 0.9% (PHQ-9) and 0.6% (GAD-7) showed symptom worsening.
• Six participants discontinued due to side effects or adverse events—an extremely low dropout rate.

These results align with, and in some cases exceed, those seen in traditional in-clinic ketamine studies, suggesting that at-home sublingual administration is both safe and highly effective.

Machine Learning Insights: Tailoring the Patient Experience

Using advanced data modeling, the study identified three distinct patient trajectories:

1. Improvement (79.3%) – Rapid and sustained reduction in symptoms
2. Chronic (11.4%) – Persistent symptoms with minimal improvement
3. Delayed Improvement (9.3%) – Gradual improvement over time

Interestingly, patients in the Delayed Improvement group were more likely to report side effects during early sessions, while Chronic responders showed increased dissociation during later stages. These insights may help clinicians better predict and personalize future KAT protocols.

Safety Profile and Monitoring

A key concern with at-home treatment is safety. However, the study demonstrated that remote monitoring and pre-treatment screening were effective in identifying and managing risks.

• Side effects were generally mild and transient.
• Serious adverse events were rare and led to only a few treatment discontinuations.
• Dissociative effects were monitored closely and were more common in Chronic responders, but did not correlate with negative outcomes.

These findings suggest that when paired with responsible telehealth support, at-home KAT can be delivered safely even outside a clinical environment.

Why This Study Matters

The Hull et al. trial is notable for several reasons:

• Scale and scope: Over 1,200 participants across varied geographies
• Real-world conditions: Reflective of practical use, not just controlled lab settings
• Innovative analytics: Machine learning applied to mental health outcomes
• High efficacy and safety: Comparable to or better than traditional in-clinic ketamine treatments

In an era where mental health needs are soaring and healthcare systems are overwhelmed, this study provides a blueprint for scalable, patient-centered care.

Limitations and Future Directions

As with any open-label study, certain limitations exist:

• Lack of a placebo or control group
• Potential for reporting bias with self-assessment tools
• Short-term outcome focus

That said, the authors advocate for follow-up studies to evaluate long-term durability of benefits, effects of repeated dosing, and integration with psychotherapeutic interventions.

Conclusion: Bringing Breakthrough Therapy Into the Home

The 2022 study by Hull et al. significantly advances the case for sublingual, at-home ketamine-assisted therapy delivered through telehealth platforms. With substantial reductions in both depression and anxiety symptoms and minimal safety concerns, this approach represents a major leap forward in mental health accessibility.

As digital health continues to evolve, combining technology with fast-acting treatments like ketamine may offer life-changing benefits for those who previously lacked access. This model not only challenges conventional paradigms but may redefine what modern, responsive, and effective mental health care looks like.

References

1. Hull TD, Malgaroli M, Gazzaley A, Akiki TJ, Madan A, Vando L, Arden K, Swain J, Klotz M, Paleos C. At-home, sublingual ketamine telehealth is a safe and effective treatment for moderate to severe anxiety and depression: Findings from a large, prospective, open-label effectiveness trial. J Affect Disord. 2022;314:59-67.
2. Reinstatler L, Youssef NA. Ketamine as a potential treatment for suicidal ideation: A systematic review of the literature. Drugs R D. 2015;15(1):37–43.
3. Dore J, Turnipseed B, Dwyer S, Turnipseed A, Andries J, Ascani G, Monnette C, Huidekoper A. Ketamine Assisted Psychotherapy (KAP): Patient demographics, clinical data and outcomes in three large clinics. J Psychoactive Drugs. 2019;51(2):189–98.
4. Feder A, Costi S, Rutter SB, Collins AB, Govindarajulu U, Jha MK, et al. A randomized controlled trial of repeated ketamine administration for chronic PTSD. Am J Psychiatry. 2021;178(2):193–202.
5. Galvez V, Li A, Huggins C, Glue P, Martin D, Somogyi AA, et al. Repetitive intranasal ketamine for treatment-resistant depression: The SYNAPSE open-label trial. J Affect Disord. 2021;282:57–66.